- Home
- DEO vs TEVA Comparison
DEO vs TEVA Comparison
Compare DEO & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEO | TEVA |
|---|---|---|
| Founded | 1886 | 1901 |
| Country | United Kingdom | Israel |
| Employees | 29860 | 32842 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4B | 33.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DEO | TEVA |
|---|---|---|
| Price | $74.92 | $29.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $109.00 | $37.38 |
| AVG Volume (30 Days) | 1.7M | ★ 6.2M |
| Earning Date | 02-25-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.42% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.67 | N/A |
| Revenue Next Year | $0.07 | $2.51 |
| P/E Ratio | $90.04 | ★ $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $72.45 | $12.47 |
| 52 Week High | $116.69 | $37.35 |
Technical Indicators
Market Signals| Indicator | DEO | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 44.83 |
| Support Level | $72.45 | $28.38 |
| Resistance Level | $98.62 | $31.99 |
| Average True Range (ATR) | 1.37 | 1.00 |
| MACD | 0.57 | 0.20 |
| Stochastic Oscillator | 50.80 | 62.59 |
Price Performance
Historical ComparisonAbout DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
About TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.